Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2010 - 12 - 07

Press release - Albatross Study: Menarini Research Against Osteoarthritis.

The enrollment and treatment phase of more than 400 patients with knee osteoarthritis have been completed. These patients are part of the Albatross Study which encompasses four countries: Italy, France, Germany, and Spain.
The aim of the Albatross Study (phase II) is to provide primary indications regarding the effectiveness of Fasitibant, an innovative drug for the treatment of intra-articular osteoarthritis, a widespread and debilitating disease especially in the elderly population.
The Fasitibant molecule results from the Menarini Group’s research in pain pathophysiology.
The Group’s research in recent years has led to the citation of 5 of its researchers in the influential ISI chart of the United States which lists research excellence worldwide.

"The first results of the Albatross Study are expected in the second quarter of 2011. In the same period we also are expecting the results of another important study, MIMOSA. This study aims to evaluate the therapeutic effectiveness of Abagovomab, an anti-cancer vaccine for the treatment of ovarian cancer which affects about 200,000 women each year in the world, and more than 60,000 in Europe. For this study, nearly 900 women were enrolled in 151 trial centers in the United States and Europe," stated Dr. Carlo Alberto Maggi, Director of Research of the Menarini Group.